Rommel Co
Adult Health · Reno, NVNPI 1548649924
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 327 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 327 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$788
- Lilly USA, LLC$562
- Pfizer$468
- Amgen$460
- GSK$457
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,149100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 62 | $1,036 |
| AstraZeneca | 38 | $788 |
| Lilly USA, LLC | 34 | $562 |
| Pfizer | 24 | $468 |
| Amgen(2 entities) | 20 | $460 |
| GSK | 27 | $457 |
| Novo Nordisk | 19 | $350 |
| Merck | 12 | $239 |
| Boehringer Ingelheim | 13 | $208 |
| Bayer | 11 | $205 |
| Idorsia Pharmaceuticals US Inc | 12 | $198 |
| Astellas Pharma US Inc | 4 | $135 |
| Edwards Lifesciences | 1 | $103 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $99 |
| Corcept Therapeutics | 4 | $77 |
| Johnson & Johnson | 3 | $70 |
| Sanofi-aventis U.S. LLC | 5 | $69 |
| Esperion Therapeutics, Inc. | 4 | $68 |
| Exact Sciences | 4 | $63 |
| Biohaven Pharmaceuticals, Inc. | 3 | $61 |
| Abbott | 3 | $57 |
| Kowa Pharmaceuticals America, Inc. | 3 | $53 |
| Sumitomo Pharma America, Inc. | 2 | $50 |
| Actelion Pharmaceuticals US, Inc. | 2 | $44 |
| Medtronic | 2 | $42 |
| Amarin Pharma, Inc. | 2 | $34 |
| Alfasigma USA, Inc. | 1 | $33 |
| Boston Scientific | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Lucid Diagnostics Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,149 in reported general payments places this provider in the 90th percentile of 90 adult health providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 69 | $88,847 |
| EliquisApixaban | 45 | $40,325 |
| XareltoRivaroxaban | 23 | $26,114 |
| JanuviaSitagliptin Phosphate | 13 | $20,923 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $18,596 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,681 |
| Atorvastatin Calcium | 406 | $7,967 |
| PremarinEstrogens, Conjugated | 16 | $5,983 |
| Ezetimibe | 87 | $4,901 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 110 | $3,522 |
| Levothyroxine Sodium | 283 | $3,518 |
| Pregabalin | 28 | $3,156 |
| Omeprazole | 137 | $2,488 |
| Losartan Potassium | 204 | $2,394 |
| Gabapentin | 103 | $2,229 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $208 | $88,84769 claims |
| PfizerEliquis, Premarin, Paxlovid | $468 | $47,73775 claims |
| Johnson & JohnsonXarelto | $70 | $26,11423 claims |
| MerckJanuvia | $239 | $20,92313 claims |
| GSKTrelegy Ellipta | $457 | $18,59613 claims |
| AstraZenecaBreztri Aerosphere | $788 | $8,68114 claims |
| AbbVieSynthroid | $1,036 | $1,57319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 90 adult health providers in Nevada.
Other adult health in Reno
- Stephanie CarlsenReno$9K
- Madhu Dewan KhatriReno$7K
- Samantha PotencianoReno$3K
- Edin AbdagicReno$3K
- Lindsay ByrneReno$2K
- Valerie JakubosReno$1K
- Brittany BeaumierReno$1K
- Renee HinojosaReno$1K
- Hector JoseReno$956
- Jessica WilkinsonReno$867
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.